Trials / Completed
CompletedNCT02640482
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 304 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of ABT-493/ABT-530 in adults with genotype 2 chronic hepatitis C virus (HCV) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-493/ABT-530 | Tablet; ABT-493 coformulated with ABT-530 |
| DRUG | Placebo for ABT-493/ABT-530 | tablet |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2016-09-01
- Completion
- 2017-02-01
- First posted
- 2015-12-29
- Last updated
- 2021-07-16
- Results posted
- 2017-09-18
Source: ClinicalTrials.gov record NCT02640482. Inclusion in this directory is not an endorsement.